Spring 2026 Co-op : Analytical Development, LNP Drug Product

Overview

Spring 2026 Co-op : Analytical Development, LNP Drug Product at Prime Medicine. Prime Medicine is a biotechnology company focused on gene editing therapies, leveraging its Prime Editing platform to develop differentiated, potentially curative genetic therapies for hematology, immunology & oncology, liver and lung programs.

Co-op Assignment Overview

Prime Medicine is seeking a diligent, motivated, and enthusiastic co-op for the Spring 2026 cycle with experience and interest in analytical technologies including HPLC, LC-MS, and capillary electrophoresis (CE). The co-op will join the analytical development (AD) team to participate in the development of separation-based analytical methods for the Prime Editor delivery platform and work cross-functionally to advance the Prime pipeline. There will be opportunities to participate in cross-functional projects essential to in vivo and ex vivo gene editing therapeutic drug development.

Primary Responsibilities

• Participate in separation-based method (HPLC, LC-MS, CE) development to assess lipid nanoparticle (LNP) drug products and their components.
• Assist senior-level scientists with buffer preparation, maintenance of instruments, and developing up-to-date analytical methods to increase in-process analytics capacity.
• Maintain detailed and accurate records of experimental data, protocols, and conclusions in an electronic notebook meeting cGMP requirements.
• Data analysis, interpretation, and presentation within the team.

Qualifications

Preferred Qualifications

What We Offer

Location

Boston, MA

Prime Medicine is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, age, sexual orientation, gender identity, disability, veteran status, or any other classification protected by law.

J-18808-Ljbffr